{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:00:32Z","timestamp":1784926832820,"version":"3.55.0"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Neoadjuvant and perioperative chemoimmunotherapy has transformed the treatment of tumors &gt;4\u00a0cm or node-positive disease (stage II to IIIA, AJCC 8th edition) in non-small cell lung cancer (NSCLC). Compared with neoadjuvant chemotherapy alone, the addition of neoadjuvant immunotherapy to chemotherapy before resection has demonstrated improved pathologic complete response rate, event-free survival, and overall survival in stage II to IIIA NSCLC. The benefit observed with pathologic response after neoadjuvant therapy expands to include patients with stage II to IIIB NSCLC with sensitizing EGFR mutations with neoadjuvant osimertinib and is being evaluated with targeted therapies in additional actionable genomic drivers. Predictive biomarkers for pathologic response after neoadjuvant or perioperative therapies and biomarkers for disease recurrence, including evaluation of minimal residual disease through liquid biopsies, are under investigation to identify NSCLC patients who may have long-term survival with neoadjuvant or perioperative treatment. This chapter summarizes the current clinical landscape of neoadjuvant, perioperative, and adjuvant therapies and updates on surgical techniques for early-stage NSCLC.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000835","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:00:14Z","timestamp":1784923214000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Early-Stage NSCLC: Novel Surgical Techniques and Neoadjuvant, Adjuvant, and Perioperative Therapies"],"prefix":"10.1097","volume":"32","author":[{"given":"So Yeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavitt","family":"Woodard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7]]},"reference":[{"key":"R1-20260724","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","article-title":"Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"R2-20260724","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"key":"R3-20260724","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa2502931","article-title":"Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N Engl J Med"},{"key":"R4-20260724","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"key":"R5-20260724","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"R6-20260724","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"key":"R7-20260724","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"key":"R8-20260724","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non\u2013small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"R9-20260724","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jtho.2024.09.069","article-title":"OA13. 03 Perioperative durvalumab for resectable NSCLC (R-NSCLC): updated outcomes from the phase 3 AEGEAN trial","volume":"19","author":"Heymach","year":"2024","journal-title":"J Thorac Oncol"},{"key":"R10-20260724","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"key":"R11-20260724","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative toripalimab plus chemotherapy for patients with resectable non\u2013small cell lung cancer: the neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"key":"R12-20260724","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2213-2600(24)00269-8","article-title":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial","volume":"13","author":"Yue","year":"2025","journal-title":"Lancet Respir Med"},{"key":"R13-20260724","doi-asserted-by":"crossref","first-page":"e241285-e","DOI":"10.1001\/jamanetworkopen.2024.1285","article-title":"Neoadjuvant-adjuvant vs neoadjuvant-only PD-1 and PD-L1 inhibitors for patients with resectable NSCLC: an indirect meta-analysis","volume":"7","author":"Zhou","year":"2024","journal-title":"JAMA Network Open"},{"key":"R14-20260724","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/jnci\/djaf190","article-title":"Immune checkpoint inhibitors as neoadjuvant therapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis","volume":"117","author":"Aburaki","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"R15-20260724","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO-24-01681","article-title":"Five-year survival outcomes with atezolizumab after chemotherapy in resected stage IB-IIIA non\u2013small cell lung cancer (IMpower010): an open-label, randomized, phase III trial","volume":"43","author":"Felip","year":"2025","journal-title":"J Clin Oncol"},{"key":"R16-20260724","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB\u2013IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O\u2019Brien","year":"2022","journal-title":"Lancet Oncol"},{"key":"R17-20260724","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1200\/JCO-25-01828","article-title":"Adjuvant durvalumab in completely resected early-stage non\u2013small cell lung cancer","volume":"44","author":"Goss","year":"2026","journal-title":"J Clin Oncol"},{"key":"R18-20260724","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.athoracsur.2024.01.004","article-title":"Neoadjuvant vs adjuvant chemoimmunotherapy for stage II-IIIB non-small cell lung cancer","volume":"118","author":"Martins","year":"2024","journal-title":"Ann Thorac Surg"},{"key":"R19-20260724","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.athoracsur.2024.09.041","article-title":"The Society of Thoracic Surgeons expert consensus on the multidisciplinary management and resectability of locally advanced non-small cell lung cancer","volume":"119","author":"Kim","year":"2025","journal-title":"Ann Thorac Surg"},{"key":"R20-20260724","doi-asserted-by":"crossref","first-page":"1569864","DOI":"10.3389\/fimmu.2025.1569864","article-title":"Efficacy of neoadjuvant, adjuvant, and perioperative immunotherapy in non-small cell lung cancer across different PD-L1 expression levels: a systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"R21-20260724","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S1470-2045(24)00498-4","article-title":"Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial","volume":"25","author":"Provencio","year":"2024","journal-title":"Lancet Oncol"},{"key":"R22-20260724","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jtho.2020.05.019","article-title":"The promises and challenges of tumor mutation burden as an immunotherapy biomarker: a perspective from the International Association for the Study of Lung Cancer Pathology Committee","volume":"15","author":"Sholl","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R23-20260724","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non\u2013small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"R24-20260724","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jamaoncol.2024.0057","article-title":"Neoadjuvant chemoimmunotherapy for NSCLC: a systematic review and meta-analysis","volume":"10","author":"Sorin","year":"2024","journal-title":"JAMA Oncol"},{"key":"R25-20260724","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1038\/s41467-025-63696-5","article-title":"Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy","volume":"16","author":"Schmid","year":"2025","journal-title":"Nat Commun"},{"key":"R26-20260724","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41591-022-02189-0","article-title":"Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial","volume":"29","author":"Cascone","year":"2023","journal-title":"Nat Med"},{"key":"R27-20260724","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.21037\/jtd-2024-2200","article-title":"Prognosis and relapse patterns in patients with non-small cell lung cancer with pathologic complete response after neoadjuvant immunochemotherapy","volume":"17","author":"Fang","year":"2025","journal-title":"J Thorac Dis"},{"key":"R28-20260724","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R29-20260724","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","article-title":"Association between pathologic response and survival after neoadjuvant therapy in lung cancer","volume":"30","author":"Deutsch","year":"2024","journal-title":"Nat Med"},{"key":"R30-20260724","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jtcvs.2025.04.028","article-title":"Lung cancer recurrence after neoadjuvant immunotherapy","volume":"170","author":"Li","year":"2025","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R31-20260724","first-page":"3519","article-title":"The predictive role of hematologic markers in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy: a retrospective cohort study","volume":"109","author":"Liu","journal-title":"Int J Surg 2023"},{"key":"R32-20260724","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2025.1115","article-title":"Neoadjuvant PD-1 and PD-L1 blockade with chemotherapy for borderline resectable and unresectable stage III non\u2013small cell lung cancer","volume":"11","author":"Ricciuti","year":"2025","journal-title":"JAMA Oncology"},{"key":"R33-20260724","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/1078-0432.CCR-25-2958","article-title":"Minimal residual disease enhances prognostic stratification beyond pathologic response in resectable non\u2013small cell lung cancer","volume":"32","author":"Provencio","year":"2026","journal-title":"Clin Cancer Res"},{"key":"R34-20260724","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non\u2013small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"R35-20260724","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non\u2013small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"R36-20260724","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.thorsurg.2025.08.004","article-title":"Neoadjuvant tyrosine kinase inhibitors","volume":"36","author":"Woodard","year":"2026","journal-title":"Thorac Surg Clin"},{"key":"R37-20260724","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO-25-00883","article-title":"Neoadjuvant osimertinib for resectable EGFR-mutated non\u2013small cell lung cancer","volume":"43","author":"He","year":"2025","journal-title":"J Clin Oncol"},{"key":"R38-20260724","doi-asserted-by":"crossref","first-page":"762","DOI":"10.21037\/jtd-20-2249","article-title":"Introduction of robotic surgery leads to increased rate of segmentectomy in patients with lung cancer","volume":"13","author":"Gergen","year":"2021","journal-title":"J Thorac Dis"},{"key":"R39-20260724","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.21037\/jtd-21-1739","article-title":"Initial experience with and surgical outcomes of da Vinci single-port system in general thoracic surgery","volume":"14","author":"Park","year":"2022","journal-title":"J Thorac Dis"},{"key":"R40-20260724","first-page":"ivaf161","article-title":"Single-port robotic-assisted approach in thoracic surgery: a prospective real-world study","volume":"40","author":"Li","year":"2025","journal-title":"Interdiscip Cardiovasc Thorac Surg"},{"key":"R41-20260724","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.21037\/tlcr-2025-460","article-title":"Advancements in 3D lung models for minimally invasive lung cancer surgery: from static to real-time dynamic modeling","volume":"14","author":"Laven","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"R42-20260724","doi-asserted-by":"crossref","first-page":"15","DOI":"10.21037\/jtd-2025-1840","article-title":"Efficacy and safety of virtual-assisted lung mapping using dual staining with indigo carmine and indocyanine green in sublobar lung resection: a single-arm prospective cohort study","volume":"18","author":"Nagano","year":"2026","journal-title":"J Thorac Dis"},{"key":"R43-20260724","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.21037\/jtd-21-1829","article-title":"Virtual-assisted lung mapping using dual staining with indocyanine green and indigo carmine enhanced marking detectability","volume":"14","author":"Yanagiya","year":"2022","journal-title":"J Thorac Dis"},{"key":"R44-20260724","first-page":"615","article-title":"Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer","volume":"60","author":"Ginsberg","year":"1995","journal-title":"Lung Cancer Study Group Ann Thorac Surg"},{"key":"R45-20260724","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(21)02333-3","article-title":"Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802\/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial","volume":"399","author":"Saji","year":"2022","journal-title":"Lancet"},{"key":"R46-20260724","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJMoa2212083","article-title":"Lobar or sublobar resection for peripheral stage IA non\u2013small-cell lung cancer","volume":"388","author":"Altorki","year":"2023","journal-title":"N Engl J Med"},{"key":"R47-20260724","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.athoracsur.2025.01.004","article-title":"Lobectomy vs sublobar resection in the society of thoracic surgeons database: importance of patient factors and lymph node evaluation","volume":"119","author":"Woodard","year":"2025","journal-title":"Ann Thorac Surg"},{"key":"R48-20260724","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jtcvs.2025.04.041","article-title":"Early compliance with lung cancer lymph node standard 5.8: an analysis of 2022 and 2023 Commission on Cancer site reviews","volume":"170","author":"Baskin","year":"2025","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R49-20260724","first-page":"100794","article-title":"Temporal trends in the utilization and survival outcomes of lobar, segmental, and wedge resection for early-stage NSCLC, 2004 to 2020","volume":"6","author":"Deng","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"R50-20260724","doi-asserted-by":"crossref","first-page":"108061","DOI":"10.1016\/j.lungcan.2024.108061","article-title":"An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer","volume":"199","author":"Houda","year":"2025","journal-title":"Lung Cancer"},{"key":"R52-20260724","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"R53-20260724","doi-asserted-by":"crossref","first-page":"116165","DOI":"10.1016\/j.ejca.2025.116165","article-title":"Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung)","volume":"233","author":"Cuppens","year":"2026","journal-title":"Eur J Cancer"},{"key":"R54-20260724","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1038\/s41591-025-03746-z","article-title":"Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial","volume":"31","author":"Cascone","year":"2025","journal-title":"Nat Med"},{"key":"R55-20260724","doi-asserted-by":"crossref","first-page":"e011773","DOI":"10.1136\/jitc-2025-011773","article-title":"NeoPred: dual-phase CT AI forecasts pathologic response to neoadjuvant chemo-immunotherapy in NSCLC","volume":"13","author":"Zheng","year":"2025","journal-title":"J Immunother Cancer"},{"key":"R56-20260724","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1186\/s12885-025-13905-7","article-title":"Prediction of pathological complete response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer using (18)F-FDG PET radiomics features of primary tumour and lymph nodes","volume":"25","author":"Liu","year":"2025","journal-title":"BMC Cancer"},{"key":"R57-20260724","doi-asserted-by":"crossref","first-page":"112171","DOI":"10.1016\/j.ejrad.2025.112171","article-title":"Non-invasive CT based multiregional radiomics for predicting pathologic complete response to preoperative neoadjuvant chemoimmunotherapy in non-small cell lung cancer","volume":"189","author":"Fan","year":"2025","journal-title":"Eur J Radiol"},{"key":"R58-20260724","doi-asserted-by":"crossref","first-page":"103551","DOI":"10.1016\/j.eclinm.2025.103551","article-title":"AI-derived longitudinal and multi-dimensional CT classifier for non-small cell lung cancer to optimize neoadjuvant chemoimmunotherapy decision: a multicentre retrospective study","volume":"89","author":"Ye","year":"2025","journal-title":"eClinicalMedicine"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000835","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:00:20Z","timestamp":1784923220000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":57,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000835","relation":{},"ISSN":["1540-336X"],"issn-type":[{"value":"1540-336X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-02-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}